PDCD1 and familial pancreatic carcinoma: LYT200 alone or in combination with anti-PD1 or chemotherapy (gemcitabine+nab-paclitaxel), will be evaluated in a recently opened phase I/II open-label, multi-centre study (NCT04666688) in patients with relapsed/refractory metastatic solid tumours, including pancreatic cancer.